Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AS 101

Drug Profile

AS 101

Alternative Names: AS101; CB-06-02; IVAX-Q-101; IVX-Q-101; Ossirene; WAX-120337

Latest Information Update: 04 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bar-Ilan University
  • Developer BioMAS; Cassiopea; Feramda
  • Class Antineoplastics; Antipsoriatics; Antivirals; Infertility therapies; Nitrogen compounds; Organometallic compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators; Integrin alpha4beta1 antagonists; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Genital warts
  • Phase I/II Wet age-related macular degeneration
  • Discontinued Acute myeloid leukaemia; Atopic dermatitis; Chemotherapy-induced damage; Female infertility; HIV infections; Male infertility; Myelodysplastic syndromes; Neurological disorders; Psoriasis; Thrombocytopenia

Most Recent Events

  • 01 Jul 2020 Feramda terminates a phase I/II trial in Wet age-related macular degeneration in Israel (PO) due to the sponsor's decision (NCT03216538)
  • 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
  • 09 Jul 2019 Phase II for Genital warts is still ongoing in Israel (Cassiopea's pipeline - July 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top